The proteasome: A worthwhile target for the treatment of solid tumours?

Amalia Milano, Rosario Vincenzo Iaffaioli, Francesco Caponigro

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Proteasomes have a fundamental function since they degrade numerous different proteins, including those involved in the regulation of the cell cycle. Proteasome inhibition is a novel approach to the treatment of solid tumours. PS-341 (bortezomib) is a small, cell-permeable molecule that selectively inhibits the proteasome binding it in a reversible manner. The proteasome has been established as an important target in haematologic malignancies and has been approved for the treatment of multiple myeloma. Bortezomib induces apoptosis of malignant cells through the inhibition of NF-κB and stabilisation of proapoptotic proteins. In preclinical studies, bortezomib also promoted chemo and radiosensitisation of malignant cells in vitro and inhibited tumour growth in murine xenografts models. The single-agent and combination studies of bortezomib in solid tumours are detailed.

Original languageEnglish
Pages (from-to)1125-1133
Number of pages9
JournalEuropean Journal of Cancer
Volume43
Issue number7
DOIs
Publication statusPublished - May 2007

Fingerprint

Proteasome Endopeptidase Complex
Neoplasms
Hematologic Neoplasms
Multiple Myeloma
Heterografts
Cell Cycle
Proteins
Bortezomib
Apoptosis
Growth

Keywords

  • Apoptosis
  • Bortezomib
  • Clinical studies
  • Cyclin-dependent kinase
  • Cyclins
  • Multiple myeloma
  • NF-κB
  • Preclinical studies
  • Proteasome
  • Solid tumours

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The proteasome : A worthwhile target for the treatment of solid tumours? / Milano, Amalia; Iaffaioli, Rosario Vincenzo; Caponigro, Francesco.

In: European Journal of Cancer, Vol. 43, No. 7, 05.2007, p. 1125-1133.

Research output: Contribution to journalArticle

Milano, Amalia ; Iaffaioli, Rosario Vincenzo ; Caponigro, Francesco. / The proteasome : A worthwhile target for the treatment of solid tumours?. In: European Journal of Cancer. 2007 ; Vol. 43, No. 7. pp. 1125-1133.
@article{906ddf3d6e0a41a8b3304648e6327f62,
title = "The proteasome: A worthwhile target for the treatment of solid tumours?",
abstract = "Proteasomes have a fundamental function since they degrade numerous different proteins, including those involved in the regulation of the cell cycle. Proteasome inhibition is a novel approach to the treatment of solid tumours. PS-341 (bortezomib) is a small, cell-permeable molecule that selectively inhibits the proteasome binding it in a reversible manner. The proteasome has been established as an important target in haematologic malignancies and has been approved for the treatment of multiple myeloma. Bortezomib induces apoptosis of malignant cells through the inhibition of NF-κB and stabilisation of proapoptotic proteins. In preclinical studies, bortezomib also promoted chemo and radiosensitisation of malignant cells in vitro and inhibited tumour growth in murine xenografts models. The single-agent and combination studies of bortezomib in solid tumours are detailed.",
keywords = "Apoptosis, Bortezomib, Clinical studies, Cyclin-dependent kinase, Cyclins, Multiple myeloma, NF-κB, Preclinical studies, Proteasome, Solid tumours",
author = "Amalia Milano and Iaffaioli, {Rosario Vincenzo} and Francesco Caponigro",
year = "2007",
month = "5",
doi = "10.1016/j.ejca.2007.01.038",
language = "English",
volume = "43",
pages = "1125--1133",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - The proteasome

T2 - A worthwhile target for the treatment of solid tumours?

AU - Milano, Amalia

AU - Iaffaioli, Rosario Vincenzo

AU - Caponigro, Francesco

PY - 2007/5

Y1 - 2007/5

N2 - Proteasomes have a fundamental function since they degrade numerous different proteins, including those involved in the regulation of the cell cycle. Proteasome inhibition is a novel approach to the treatment of solid tumours. PS-341 (bortezomib) is a small, cell-permeable molecule that selectively inhibits the proteasome binding it in a reversible manner. The proteasome has been established as an important target in haematologic malignancies and has been approved for the treatment of multiple myeloma. Bortezomib induces apoptosis of malignant cells through the inhibition of NF-κB and stabilisation of proapoptotic proteins. In preclinical studies, bortezomib also promoted chemo and radiosensitisation of malignant cells in vitro and inhibited tumour growth in murine xenografts models. The single-agent and combination studies of bortezomib in solid tumours are detailed.

AB - Proteasomes have a fundamental function since they degrade numerous different proteins, including those involved in the regulation of the cell cycle. Proteasome inhibition is a novel approach to the treatment of solid tumours. PS-341 (bortezomib) is a small, cell-permeable molecule that selectively inhibits the proteasome binding it in a reversible manner. The proteasome has been established as an important target in haematologic malignancies and has been approved for the treatment of multiple myeloma. Bortezomib induces apoptosis of malignant cells through the inhibition of NF-κB and stabilisation of proapoptotic proteins. In preclinical studies, bortezomib also promoted chemo and radiosensitisation of malignant cells in vitro and inhibited tumour growth in murine xenografts models. The single-agent and combination studies of bortezomib in solid tumours are detailed.

KW - Apoptosis

KW - Bortezomib

KW - Clinical studies

KW - Cyclin-dependent kinase

KW - Cyclins

KW - Multiple myeloma

KW - NF-κB

KW - Preclinical studies

KW - Proteasome

KW - Solid tumours

UR - http://www.scopus.com/inward/record.url?scp=34247125164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247125164&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2007.01.038

DO - 10.1016/j.ejca.2007.01.038

M3 - Article

C2 - 17379504

AN - SCOPUS:34247125164

VL - 43

SP - 1125

EP - 1133

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7

ER -